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INCREASED EXPRESSION OF ARTHRITIC MARKER GENES IN THE
CARTILAGE OF SIRT1 NULL MICE
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Purpose: Osteoarthritis (OA), the most frequent age related disease present
in the west, is a multi-factorial imbalance between cartilage anabolism and
catabolism. To understand the mechanisms underlying OA, we focused on
the protein deacetylase SirT1, a factor known to prolong organism lifespan.
SirT1 has been previously shown to regulate apoptosis and cartilage-
speciﬁc gene expression in human chondrocytes. Recent data also indicates
that SirT1 is a potent inhibitor of the matrix metalloproteinases (MMPs).
MMPs are the most well known of arthritis marker genes that play a
central role in cartilage degeneration. In order to evaluate the role of SirT1
in cartilage homeostasis, we assessed MMP and ADAMTS expression in the
cartilage of SirT1 null mice.
Method: We used SirT1 Wild-type (WT) and SirT1 Null mice in the analysis.
The SirT1 Null mice do not express SirT1. Articular cartilage was harvested
from hind paws in 1 to 3 week old mice. The cartilage was processed for
both immunohistochemistry and subculture of chondrocytes.
Results: Articular cartilage tissue sections from SirT1 Null mice exhibited
low levels of type 2 collagen, aggrecan and glycosaminoglycans (GAG)
compared to SirT1 WT mice at 1 week or 3 weeks. Protein levels of
aggrecan and type 2 collagen were also decreased in the chondrocytes
derived from SirT1 Null mice. In contrast, protein levels of MMP-3, MMP-8,
MMP-9 and MMP-13 were elevated in the SirT1 Null mice compared to
WT. Finally, DBC1 (deleted in breast carcinoma 1), a known Sirt1 associated
protein that represses SirT1 enzymatic activity, was found to be elevated in
the SirT1 Null mice compared to WT.
Conclusion: The data from this animal model indicate that SirT1 is
a negative regulator of the genes responsible for cartilage degradation
in arthritis; namely the MMPs and DBC1. The role of SirT1 as a pu-
tative anti-arthritic gene is consistent with its general function as an
anti-aging/anti-inﬂammatory protein.
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Purpose: The STR/ort mice develop spontaneous osteoarthritis (OA) of the
knee, and are believed to be a relevant model for human knee OA. We have
recently shown that treatment with either glucosamine sulfate or an MMP
and aggrecanase inhibitor reduced the severity of the OA histological score
as well as histomorphometric parameters in this strain. To further validate
this model for drug discovery purposes, we investigated its responsiveness
to further interventions within strategies currently pursued for OA treat-
ment. We investigated in two separate studies the effects of an EP4 speciﬁc
antagonist, or of a speciﬁc aggrecanase inhibitor, respectively, in STR/ort
mice.
Methods: As a speciﬁc EP4 receptor antagonist we used CJ-042,794
(Murase et al., 2008). Wyeth’s compound #8OO described in patent WO
2007/008994 was used as an aggrecanase1/2 speciﬁc inhibitor (ASI).
STR/ort male mice were recruited at 5 months of age (n=20-22). Com-
pounds were administered orally once daily for 3 months, 3 and 30 mg/kg
CJ-042,794, and 60 and 150 mg/kg ASI; vehicle was 0.1% methocel for both
experiments. At the end of treatment, the animals were euthanized and the
knee joints collected, processed for histology and blindly scored according
to both Mankin’s and the OARSI method. Statistical analysis was performed
by the Student’s t test or by ANOVA followed by Dunn’s or Dunnett’s tests
comparing all treatment groups vs. vehicle.
For both compounds the plasma levels were monitored in limited phar-
macokinetic studies in the STR/ort mouse to conﬁrm the exposure at
pharmacological relevant concentrations.
Results: After three months of daily treatment, vehicle-treated animals
displayed severe OA with clefting and erosion of the articular cartilage
to the subchondral bone, with prominent chondroosseous metaplasias and
often inﬂammation and pannus. No improvement whatsoever was associ-
ated with treatment with the EP4 antagonist CJ-042,794 at either dose, at
least in histopathological parameters, despite the animals were exposed to
circulating levels well above its IC50 [approx. 10 nM] on EP4 receptors (e.g.,
3 h after administration plasma concentration was 15 μg/ml [35 μM]).
Conversely, we observed a signiﬁcant albeit slight decrease of OARSI score
and total score following treatment with the ASI, at the higher dose (200
mg/kg). Pharmacokinetic analyses for ASI (Cmax=102 μg/mL [214 μM], T1/2
=2h, AUC 0-24h=198 μg.h/mL), conﬁrmed that these animals were exposed
to circulating levels above the aggrecanase inhibiting concentrations [92
nM and186 nM vs. aggrecanase 1 and 2, respectively).
Conclusions: The present studies conﬁrm the STR/ort mouse as a model of
choice for evaluating OA disease modifying drugs. Moreover, they further
establish aggrecanase inhibition as a disease-modifying approach, while
suggest that EP4 antagonism is mainly an OA pain-controlling strategy.
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Purpose: Both to enhance basic knowledge of osteoarthritis (OA) develop-
ment and to test the effect of disease modifying OA drugs (DMOADs), a
large need for proper (small) animal models exists. Mostly, these models
make use of either enzymatic or chemical intra-articular injections or
surgical induced instability.
In 1998 a model for OA was described that induced OA in rats through
strenuous exercise evoked by intra-cranial stimulation. This model has
been modiﬁed using a (more practical) rodent treadmill with electric shock
stimuli to force running for a period of six weeks. Several studies have used
this model to study the effect of different DMOADs.
The goal of the current study was to investigate which early signs of
OA could be detected using in-vivo contrast-enhanced microCT (CECT) in
Wistar rats that were forced to run for 30 kilometres over a six week
period. Second, we investigated if the induced OA was progressive after the
running stimulus was stopped after six weeks.
Methods: Six male Wistar rats were trained for one week to run in a rodent
treadmill machine as follows: day 1, 10 minutes at 0.60 km/hr; day 2 15
minutes at 0.72 km/hr; day 3 20 minutes at 0.90 km/hr; day 4 30 minutes
at 1.08 km/hr and day 5 35 minutes at 1.20 km/hr. The following 5 weeks,
the rats were forced to run for ﬁve days a week, the ﬁrst 10 minutes at 0.72
km/hr in order to warm-up and the following 50 minutes at 1.20 km/hr.
All knee joints of all animals were scanned with CECT at the start of the
experiment (t = 0) and directly after running at t = 1, 3, 6 weeks. After 70μl
intra-articular injection with ioxaglate into their knee joint, the negative
charged contrast agent (ioxaglate) enabled to measure both quantitative
(volume) and qualitative (GAG-content) changes in cartilage tissue over
time. At six weeks the running exercise stopped, a subsequent CECT scan
was performed at 12, 18 and 24 weeks. In this abstract we present all
CECT-data for condylar, patellar and trochlear cartilage up to 12 weeks
follow-up.
Results: After three (p=0.02) and six weeks (p=0.01) of running signiﬁ-
cant higher attenuation values were detected, indicating GAG loss from
condylar cartilage. At 12 weeks (6 weeks after running was stopped)
the total volume of condylar cartilage was signiﬁcant reduced, indicating
OA progression (p=0.02) (Figure 1). Patellar cartilage attenuation was not
Figure 1. Condyle.
